An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse.
OBJECTIVE
Retinal degenerations are a leading cause of blindness for which there are currently no effective treatments. This has stimulated interest in the investigation of gene therapy strategies for these diseases in a variety of animal models. A number of attempts have been made to prevent photoreceptor loss in the rd mouse model of retinal degeneration using adenoviral vectors containing either a copy of the missing functional gene or a gene encoding either a neurotrophic factor or an antiapoptotic factor. The authors have previously demonstrated that intraocular administration of an adenoviral vector containing a beta galactosidase gene (AV.LacZ) results in an immune response to viral gene products and beta galactosidase. Here the effect of the immune response on retinal degeneration is examined.


METHODS
Juvenile rd mice were injected intravitreally with AV.LacZ and a proportion were depleted of either CD4+ or CD8+ T cells or both. Control animals were injected with PBS. The mice were sacrificed 10 and 20 days post-injection and their eyes embedded in paraffin wax and sectioned.


RESULTS
10 days after intravitreal injection of AV.LacZ, the outer nuclear layer contains an average of 2.5 rows compared with 1.5 in PBS injected animals (p<0.005). The protective effect of AV.LacZ is negated by immune suppression and does not extend beyond 20 days.


CONCLUSIONS
An immune response to vector and transgene products is able to slow degeneration in the rd mouse. This phenomenon should be taken into account when analysing the degeneration in the rd mouse following gene transfer.
University Eye Hospital, Liebigstrasse 10-14, D-04103 Leipzig, Germany.
M B
MB
Reichel
J
J
Bainbridge
D
D
Baker
A J
AJ
Thrasher
S S
SS
Bhattacharya
R R
RR
Ali
D000256:Adenoviridae / Q000235:genetics / Q000276:immunology; D000818:Animals; D002452:Cell Count; D017930:Genes, Reporter; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000276:immunology*; D007108:Immune Tolerance / Q000276:immunology; D007165:Immunosuppression Therapy; D051379:Mice; D008809:Mice, Inbred C3H; D016612:Paraffin Embedding; D020419:Photoreceptor Cells, Vertebrate; D012162:Retinal Degeneration / Q000276:immunology / Q000628:therapy*; D018709:Statistics, Nonparametric; D001616:beta-Galactosidase / Q000235:genetics* / Q000276:immunology
D001616:beta-Galactosidase